Beyond UBE3A: New Conversations About Genotype, Variants, and Future Treatments
At INSYNC-AS 2026, researchers came together to examine how genes beyond UBE3A and differences within UBE3A itself may shape Angelman syndrome and future therapeutic development. Why can Angelman syndrome (AS) look different from one person to another, even when the diagnosis is the same? And could understanding those differences help researchers develop better treatment approaches […]
Inside INSYNC-AS 2025: Progress, Partnership, and Possibilities for Angelman Syndrome
The 5th Annual INSYNC-AS Meeting brought together top researchers to tackle brain-targeted drug delivery, sharing breakthroughs in blood-brain barrier crossing for Angelman syndrome therapies.